United Therapeutics Corp (UTHR)
376.80
+2.78
(+0.74%)
USD |
NASDAQ |
Nov 04, 16:00
375.52
-1.28
(-0.34%)
Pre-Market: 08:50
United Therapeutics Enterprise Value: 13.90B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 13.90B |
| November 01, 2024 | 13.77B |
| October 31, 2024 | 13.77B |
| October 30, 2024 | 13.21B |
| October 29, 2024 | 12.82B |
| October 28, 2024 | 12.69B |
| October 25, 2024 | 12.64B |
| October 24, 2024 | 12.71B |
| October 23, 2024 | 12.81B |
| October 22, 2024 | 13.59B |
| October 21, 2024 | 13.61B |
| October 18, 2024 | 13.51B |
| October 17, 2024 | 13.71B |
| October 16, 2024 | 13.58B |
| October 15, 2024 | 13.12B |
| October 14, 2024 | 13.01B |
| October 11, 2024 | 13.06B |
| October 10, 2024 | 12.88B |
| October 09, 2024 | 12.99B |
| October 08, 2024 | 12.95B |
| October 07, 2024 | 12.68B |
| October 04, 2024 | 12.95B |
| October 03, 2024 | 12.69B |
| October 02, 2024 | 12.80B |
| October 01, 2024 | 13.04B |
| Date | Value |
|---|---|
| September 30, 2024 | 13.06B |
| September 27, 2024 | 13.48B |
| September 26, 2024 | 13.44B |
| September 25, 2024 | 13.52B |
| September 24, 2024 | 13.45B |
| September 23, 2024 | 13.35B |
| September 20, 2024 | 13.23B |
| September 19, 2024 | 13.16B |
| September 18, 2024 | 12.77B |
| September 17, 2024 | 12.88B |
| September 16, 2024 | 12.88B |
| September 13, 2024 | 12.62B |
| September 12, 2024 | 12.70B |
| September 11, 2024 | 12.93B |
| September 10, 2024 | 12.76B |
| September 09, 2024 | 13.04B |
| September 06, 2024 | 12.91B |
| September 05, 2024 | 13.10B |
| September 04, 2024 | 13.25B |
| September 03, 2024 | 13.21B |
| August 30, 2024 | 13.70B |
| August 29, 2024 | 13.56B |
| August 28, 2024 | 13.54B |
| August 27, 2024 | 13.07B |
| August 26, 2024 | 12.95B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.848B
Minimum
Mar 18 2020
13.90B
Maximum
Nov 04 2024
7.651B
Average
7.996B
Median
Apr 13 2021
Enterprise Value Benchmarks
| Liquidia Corp | 749.50M |
| Pfizer Inc | 219.16B |
| Tonix Pharmaceuticals Holding Corp | 7.452M |
| Ardelyx Inc | 1.305B |
| Entrada Therapeutics Inc | 190.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 309.10M |
| Revenue (Quarterly) | 748.90M |
| Total Expenses (Quarterly) | 340.70M |
| EPS Diluted (Quarterly) | 6.39 |
| Gross Profit Margin (Quarterly) | 88.90% |
| Profit Margin (Quarterly) | 41.27% |
| Earnings Yield | 6.04% |
| Operating Earnings Yield | 7.30% |
| Normalized Earnings Yield | 6.327 |